In the general population, surveillance can be associated with overdiagnosis and overtreatment with no evidence for improved short-term survival (10-year period). However, there is preliminary evidence for value in surveillance of individuals with BRCA pathogenic variantsr as data suggests that BRCA-related prostate cancer is aggressive with a higher probability of distant metastasis and occurs at a younger age than sporadic prostate cancer.r
Carriers of a HOXB13 G84E pathogenic variant are reported to have higher rates of young onset prostate cancer (diagnosed age 55 years and under)rr and have been shown to have prostate cancer risks comparable to carriers of a BRCA2 pathogenic variant (OR 3.88, 95% CI 2.85-5.24) in a large population-based cohort.r
The HOXB13 G84E pathogenic variant is prevalent in more than 1% of the Swedish population.r Founder variants in HOXB13 have been identified in individuals with prostate cancer in other ethnic subpopulations,rr however, these remain variants of uncertain significance at this time.
The risk of prostate cancer in individuals with a HOXB13 G84E pathogenic variant is modified by family history.rr
There is no demonstrable increase in breast cancer risk in carriers of the HOXB13 G84E pathogenic variant.r